BR112022021040A2 - Métodos e composições para o tratamento de câncer de próstata - Google Patents

Métodos e composições para o tratamento de câncer de próstata

Info

Publication number
BR112022021040A2
BR112022021040A2 BR112022021040A BR112022021040A BR112022021040A2 BR 112022021040 A2 BR112022021040 A2 BR 112022021040A2 BR 112022021040 A BR112022021040 A BR 112022021040A BR 112022021040 A BR112022021040 A BR 112022021040A BR 112022021040 A2 BR112022021040 A2 BR 112022021040A2
Authority
BR
Brazil
Prior art keywords
methods
prostate cancer
compositions
treatment
solid dosage
Prior art date
Application number
BR112022021040A
Other languages
English (en)
Inventor
Balázs Kárpáti Richard
ÖTVÖS Zsolt
JORDÁN Tamás
Ujhelyi Andrea
BASA-DÉNES Orsolya
Solymosi Tamás
Glavinas Hristos
P Capone Dominic
Manning Duus Elizabeth
E Friend Ii John
Original Assignee
Tavanta Therapeutics Hungary Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tavanta Therapeutics Hungary Incorporated filed Critical Tavanta Therapeutics Hungary Incorporated
Publication of BR112022021040A2 publication Critical patent/BR112022021040A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

MÉTODOS E COMPOSIÇÕES PARA O TRATAMENTO DE CÂNCER DE PRÓSTATA. A invenção se refere a métodos e composições para o tratamento de câncer de próstata. Mais particularmente, os métodos para o tratamento de câncer de próstata compreendem administrar acetato de abiraterona sob a forma de uma forma de dosagem sólida para administração oral, sendo que a dita forma de dosagem sólida para administração oral é capaz de reconstituição ou desintegração rápida na cavidade oral ou em uma alíquota de líquido antes da ingestão, adequadamente administrada em combinação com um esteroide.
BR112022021040A 2020-04-16 2021-04-15 Métodos e composições para o tratamento de câncer de próstata BR112022021040A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011023P 2020-04-16 2020-04-16
PCT/IB2021/053116 WO2021209945A1 (en) 2020-04-16 2021-04-15 Methods and compositions for treating prostate cancer

Publications (1)

Publication Number Publication Date
BR112022021040A2 true BR112022021040A2 (pt) 2022-12-06

Family

ID=75954149

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021040A BR112022021040A2 (pt) 2020-04-16 2021-04-15 Métodos e composições para o tratamento de câncer de próstata

Country Status (11)

Country Link
US (1) US20230158047A1 (pt)
EP (1) EP4135659A1 (pt)
JP (1) JP2023521498A (pt)
KR (1) KR20220166856A (pt)
CN (1) CN115427016A (pt)
AU (1) AU2021257675A1 (pt)
BR (1) BR112022021040A2 (pt)
CA (1) CA3175658A1 (pt)
IL (1) IL297338A (pt)
MX (1) MX2022013043A (pt)
WO (1) WO2021209945A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403078A1 (fr) 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
DE8703104U1 (pt) 1987-02-28 1987-04-16 Heeg, Otto, 6450 Hanau, De
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
GB9904049D0 (en) 1999-02-22 1999-04-14 Quadrant Holdings Cambridge Rapidly-soluble compositions
EP1585502B9 (en) 2002-11-12 2012-05-09 Elan Pharma International Limited Fast-disintegrating solid dosage forms being not friable and comprising pullulan
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
CN109125276A (zh) * 2017-06-19 2019-01-04 齐鲁制药有限公司 一种醋酸阿比特龙片剂的药物组合物及其制备方法
US20210008081A1 (en) * 2018-03-29 2021-01-14 Leiutis Pharmaceuticals Pvt, Ltd Oral liquid formulations of abiraterone

Also Published As

Publication number Publication date
MX2022013043A (es) 2023-01-24
IL297338A (en) 2022-12-01
KR20220166856A (ko) 2022-12-19
CA3175658A1 (en) 2021-10-21
JP2023521498A (ja) 2023-05-24
EP4135659A1 (en) 2023-02-22
WO2021209945A1 (en) 2021-10-21
CN115427016A (zh) 2022-12-02
US20230158047A1 (en) 2023-05-25
AU2021257675A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
GEP20156281B (en) Orally administered corticosteroid compositions
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
BR112015004244A2 (pt) composição médica oralmente administrada
ECSP10010011A (es) Composición farmacéutica que comprende la combinación de diversos agentes venotónicos vasoprotectores para el tratamiento de la insuficiencia venosa crónica
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
BR112017027688A2 (pt) Composições orais que contêm éster de 17- hidroxiprogesterona e métodos relacionados
ES2315662T3 (es) Formulaciones para el tratamiento de afecciones artriticas.
BR112015019264A8 (pt) cápsulas para o tratamento de helicobacter pylori e seu uso".
BR112019002513A2 (pt) uso e dosagem de agentes terapêuticos para endometriose
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
JP2019532112A5 (ja) 結節性痒疹を治療するための抗掻痒剤
BR112022021040A2 (pt) Métodos e composições para o tratamento de câncer de próstata
BR112015019776A2 (pt) comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos
ECSP10010054A (es) Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas
BR112022021141A2 (pt) Regime de dosagem para o tratamento de câncer
BRPI1010325B1 (pt) composição dermatológica e/ou farmacêutica, dispositivo médico e seus usos
Okhovatfard et al. Effect of Curcuma longa and its derivatives, curcumin and curcuminoids on treatment of oral lichen planus: A systematic review of clinical evidence
BR112022026558A2 (pt) Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo
Waraich et al. A comparative study to assess the safety and efficacy of etoricoxib versus aceclofenac in osteoarthritis
Ropert et al. Colchicine is an active treatment for everolimus-induced oral ulcers
RU2771015C2 (ru) Фармацевтическая композиция в виде мази для лечения геморроя
Wang et al. Research on mechanisms of chinese medicines in prevention and treatment of postoperative adhesion
ECSP099650A (es) Composiciones farmacéuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima 5 -reductasa y un antagonista de los receptores 1 -adrenergicos
AR080936A1 (es) Composicion de yodo molecular de uso humano para la prevencion y tratamiento de patologias prostaticas. uso.
Qian et al. Molecular targets associated with ulcerative colitis and the benefits of atractylenolides-based therapy